Table 1 Baseline characteristics
No DM | DM | p-value | |
|---|---|---|---|
Number: | 68,433 | 9,797 | |
Percentage of study population: | 87.5 | 12.5 | |
Gender, female (%) | 36.1 | 39.4 | <0.0001 |
Age at hospitalization (years ± SD ) | 68.1 (±13.2) | 69.2 (±11.8) | <0.0001 |
Period of hospitalization (%) | |||
1997–2002 | 87.9 | 12.1 | |
2003–2006 | 86.9 | 13.1 | |
Secondary prevention claimed 1997–2002 (%) | 40,982 | 5,649 | |
ASA | 39.1 | 37.4 | <0.0149 |
ACEIs/ARBs | 36.4 | 55.1 | <0.0001 |
β-blockers | 69.8 | 64.8 | <0.0001 |
Clopidogrel | 17.0 | 14.1 | <0.0001 |
Statins | 41.6 | 39.1 | <0.0003 |
Secondary prevention claimed 2003–2006 (%) | 27,451 | 4,148 | |
ASA | 70.5 | 64.3 | <0.0001 |
ACEIs/ARBs | 48.0 | 66.3 | <0.0001 |
β-blockers | 78.2 | 75.8 | <0.0005 |
Clopidogrel | 66.9 | 62.2 | <0.0001 |
Statins | 77.3 | 77.5 | 0.8050 |
Comorbidity diseases (%) | |||
Cardiac dysrhythmias | 10.2 | 11.1 | <0.0038 |
Heart failure | 17.4 | 27.5 | <0.0001 |
Pulmonary edema | 1.0 | 1.8 | <0.0001 |
Shock | 0.9 | 1.5 | <0.0001 |
Cerebrovascular disease | 4.4 | 7.2 | <0.0001 |
Renal disease | 1.5 | 3.5 | <0.0001 |
Diabetes complications | 0.5 | 33.1 | <0.0001 |
Malignancy | 0.5 | 0.5 | 0.2953 |
Concomitant pharmacotherapy | |||
Loop diuretics | 35.1 | 54.4 | <0.0001 |
Proton pump inhibitors | 18.1 | 21.2 | <0.0001 |
Reperfusion therapy | |||
Percutaneous coronary intervention | 28.0 | 21.8 | <0.0001 |
Coronary artery by-pass graft | 4.8 | 5.9 | <0.0001 |